• Something wrong with this record ?

Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI)

Z. Straňák, E. Saliba, P. Kosma, K. Posfay-Barbe, K. Yunis, T. Farstad, K. Unnebrink, J. van Wyk, C. Wegzyn, G. Notario, S. Kalus, FJ. Campbell,

. 2016 ; 11 (6) : e0157446. [pub] 20160616

Language English Country United States

Document type Journal Article, Multicenter Study, Observational Study

Persistent link   https://www.medvik.cz/link/bmc17031651

BACKGROUND: Preterm infants are at high risk of developing respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI). This observational epidemiologic study evaluated RSV disease burden and risk factors for RSV-associated LRTI hospitalization in preterm infants 33 weeks+0 days to 35 weeks+6 days gestational age not receiving RSV prophylaxis. METHODS: Preterm infants ≤6 months of age during RSV season (1 October 2013-30 April 2014) were followed at 72 sites across 23 countries from September 2013-July 2014 (study period). RSV testing was performed according to local clinical practice. Factors related to RSV-associated hospitalization for LRTI were identified using multivariable logistic regression with backward selection. RESULTS: Of the 2390 evaluable infants, 204 and 127 were hospitalized for LRTI during the study period and RSV season, respectively. Among these subjects, 64/204 and 46/127, respectively, were hospitalized for confirmed RSV LRTI. Study period and RSV season normalized RSV hospitalization rates (per 100 infant years) were 4.1 and 6.1, respectively. Factors associated with an increased risk of RSV-related LRTI hospitalization in multivariable analyses were smoking of family members (P<0.0001), non-hemodynamically significant congenital heart disease diagnosis (P = 0.0077), maternal age of ≤25 years at delivery (P = 0.0009), low maternal educational level (P = 0.0426), household presence of children aged 4 to 5 years (P = 0.0038), age on 1 October ≤3 months (P = 0.0422), and presence of paternal atopy (P<0.0001). CONCLUSIONS: During the 2013-2014 RSV season across 23 countries, for preterm infants 33-35 weeks gestation ≤6 months old on 1 October not receiving RSV prophylaxis, confirmed RSV LRTI hospitalization incidence was 4.1 per 100 infant years during the study period and 6.1 per 100 infant years during the RSV season. This study enhances the findings of single-country studies of common risk factors for severe RSV infection in preterm infants and suggests that combinations of 4-6 risk factors may be used to accurately predict risk of RSV hospitalization. These findings may be useful in the identification of infants most at risk of severe RSV infection.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031651
003      
CZ-PrNML
005      
20171025123107.0
007      
ta
008      
171025s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0157446 $2 doi
035    __
$a (PubMed)27310438
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Straňák, Zbyněk $u Institute for the Care of Mother and Child, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
245    10
$a Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI) / $c Z. Straňák, E. Saliba, P. Kosma, K. Posfay-Barbe, K. Yunis, T. Farstad, K. Unnebrink, J. van Wyk, C. Wegzyn, G. Notario, S. Kalus, FJ. Campbell,
520    9_
$a BACKGROUND: Preterm infants are at high risk of developing respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI). This observational epidemiologic study evaluated RSV disease burden and risk factors for RSV-associated LRTI hospitalization in preterm infants 33 weeks+0 days to 35 weeks+6 days gestational age not receiving RSV prophylaxis. METHODS: Preterm infants ≤6 months of age during RSV season (1 October 2013-30 April 2014) were followed at 72 sites across 23 countries from September 2013-July 2014 (study period). RSV testing was performed according to local clinical practice. Factors related to RSV-associated hospitalization for LRTI were identified using multivariable logistic regression with backward selection. RESULTS: Of the 2390 evaluable infants, 204 and 127 were hospitalized for LRTI during the study period and RSV season, respectively. Among these subjects, 64/204 and 46/127, respectively, were hospitalized for confirmed RSV LRTI. Study period and RSV season normalized RSV hospitalization rates (per 100 infant years) were 4.1 and 6.1, respectively. Factors associated with an increased risk of RSV-related LRTI hospitalization in multivariable analyses were smoking of family members (P<0.0001), non-hemodynamically significant congenital heart disease diagnosis (P = 0.0077), maternal age of ≤25 years at delivery (P = 0.0009), low maternal educational level (P = 0.0426), household presence of children aged 4 to 5 years (P = 0.0038), age on 1 October ≤3 months (P = 0.0422), and presence of paternal atopy (P<0.0001). CONCLUSIONS: During the 2013-2014 RSV season across 23 countries, for preterm infants 33-35 weeks gestation ≤6 months old on 1 October not receiving RSV prophylaxis, confirmed RSV LRTI hospitalization incidence was 4.1 per 100 infant years during the study period and 6.1 per 100 infant years during the RSV season. This study enhances the findings of single-country studies of common risk factors for severe RSV infection in preterm infants and suggests that combinations of 4-6 risk factors may be used to accurately predict risk of RSV hospitalization. These findings may be useful in the identification of infants most at risk of severe RSV infection.
650    _2
$a stupeň vzdělání $7 D004522
650    _2
$a Evropa $x epidemiologie $7 D005060
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a gestační stáří $7 D005865
650    _2
$a vrozené srdeční vady $x komplikace $7 D006330
650    _2
$a hospitalizace $x statistika a číselné údaje $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a novorozenec $7 D007231
650    _2
$a novorozenec nedonošený $7 D007234
650    _2
$a věk matky $7 D008423
650    _2
$a Střední východ $x epidemiologie $7 D008877
650    _2
$a multivariační analýza $7 D015999
650    _2
$a prognóza $7 D011379
650    _2
$a infekce respiračními syncytiálními viry $x diagnóza $x epidemiologie $x etiologie $x virologie $7 D018357
650    _2
$a respirační syncytiální viry $x izolace a purifikace $x patogenita $x fyziologie $7 D012136
650    _2
$a infekce dýchací soustavy $x diagnóza $x epidemiologie $x etiologie $x virologie $7 D012141
650    _2
$a rizikové faktory $7 D012307
650    _2
$a znečištění tabákovým kouřem $x škodlivé účinky $7 D014028
650    _2
$a Spojené státy americké $x epidemiologie $7 D014481
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Saliba, Elie $u Inserm U930, Université François Rabelais, and Department of Neonatology, University Hospital Clocheville, Tours, France.
700    1_
$a Kosma, Paraskevi $u Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Posfay-Barbe, Klara $u Department of Pediatrics, Geneva Medical School and University Hospitals of Geneva, Geneva, Switzerland.
700    1_
$a Yunis, Khalid $u Department of Pediatrics and Adolescent Medicine, American University of Beirut, Riad El Solh, Beirut, Lebanon.
700    1_
$a Farstad, Teresa $u Department of Pediatrics, Akershus University Hospital, Lørenskog, Norway.
700    1_
$a Unnebrink, Kristina $u Data and Statistical Sciences, AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany.
700    1_
$a van Wyk, Jean $u Virology, AbbVie Inc., North Chicago, IL, United States of America.
700    1_
$a Wegzyn, Colleen $u Neonatology, AbbVie Inc., North Chicago, IL, United States of America.
700    1_
$a Notario, Gerard $u Virology, AbbVie Inc., North Chicago, IL, United States of America.
700    1_
$a Kalus, Stefanie $u Biostatistics, GKM Gesellschaft für Therapieforschung mbH, Munich, Germany.
700    1_
$a Campbell, Fiona J $u Neonatology and HIV, AbbVie Ltd, Dublin, Ireland.
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 11, č. 6 (2016), s. e0157446
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27310438 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20171025123149 $b ABA008
999    __
$a ok $b bmc $g 1255244 $s 992678
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c 6 $d e0157446 $e 20160616 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options